Who Optimizes SG&A Costs Better? CymaBay Therapeutics, Inc. or Soleno Therapeutics, Inc.

Biotech Giants: Who Manages SG&A Costs Better?

__timestampCymaBay Therapeutics, Inc.Soleno Therapeutics, Inc.
Wednesday, January 1, 201481850002917513
Thursday, January 1, 201588710007878291
Friday, January 1, 201696450008366794
Sunday, January 1, 2017123870006610381
Monday, January 1, 2018143810006556000
Tuesday, January 1, 2019192380006930000
Wednesday, January 1, 2020174250008758000
Friday, January 1, 20212304000010806000
Saturday, January 1, 2022251160009844000
Sunday, January 1, 20235195300013481000
Loading chart...

Unveiling the hidden dimensions of data

Optimizing SG&A Costs: A Tale of Two Biotechs

In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Over the past decade, CymaBay Therapeutics, Inc. and Soleno Therapeutics, Inc. have taken different paths in optimizing these costs. From 2014 to 2023, CymaBay's SG&A expenses surged by over 500%, peaking in 2023. This reflects their aggressive expansion strategy. In contrast, Soleno maintained a more conservative approach, with expenses increasing by approximately 360% over the same period. Notably, CymaBay's expenses in 2023 were nearly four times higher than Soleno's, indicating a significant divergence in their operational strategies. This data highlights the strategic choices companies make in balancing growth and cost management, offering valuable insights for investors and industry analysts alike.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025